{"id":"gemcitabine-rituximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing strand breaks and apoptosis in rapidly dividing cells. Rituximab is a chimeric monoclonal antibody against CD20 that depletes B cells through antibody-dependent cellular cytotoxicity and direct induction of apoptosis. Together, they provide synergistic cytotoxic and immunologic effects against B-cell malignancies.","oneSentence":"Gemcitabine damages cancer cell DNA while rituximab targets and eliminates B cells expressing CD20, combining chemotherapy with immunotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:55.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":360},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT07432022","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2026-03-01","conditions":"Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07","enrollment":115},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT07389356","phase":"NA","title":"Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-25","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":70},{"nctId":"NCT04161248","phase":"EARLY_PHASE1","title":"Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-09-02","conditions":"Lymphoma, B-Cell","enrollment":18},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT07365306","phase":"PHASE2","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-12-30","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma","enrollment":43},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT04182204","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":270},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT06929624","phase":"PHASE3","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":280},{"nctId":"NCT03259503","phase":"PHASE1","title":"Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":50},{"nctId":"NCT04442022","phase":"PHASE2, PHASE3","title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-09-03","conditions":"Relapsed/Refractory Diffuse Large B-cell Lymphoma","enrollment":501},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT05498220","phase":"PHASE2","title":"Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-02-17","conditions":"Diffuse Large B-cell Lymphoma","enrollment":5},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT07081022","phase":"PHASE2","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-08-17","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":180},{"nctId":"NCT07124936","phase":"PHASE1, PHASE2","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":97},{"nctId":"NCT07122609","phase":"PHASE2","title":"Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-05","conditions":"Relapsed and Refractory DLBCL","enrollment":22},{"nctId":"NCT05279300","phase":"PHASE1","title":"A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2022-03-28","conditions":"Advanced Solid Tumor, Advanced Lymphoma","enrollment":480},{"nctId":"NCT05276310","phase":"PHASE1","title":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","status":"RECRUITING","sponsor":"ImmuneOncia Therapeutics Inc.","startDate":"2022-06-02","conditions":"Advanced Cancer","enrollment":62},{"nctId":"NCT07001540","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":130},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT02953509","phase":"PHASE1, PHASE2","title":"Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-11-21","conditions":"Non Hodgkin Lymphoma","enrollment":178},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT06244368","phase":"PHASE2","title":"GVM±R in Patients With Relapsed or Refractory Aggressive NHL.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-01-17","conditions":"Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":115},{"nctId":"NCT05299164","phase":"PHASE1","title":"GVM±R in Patients With Relapsed or Refractory Aggressive NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-05-15","conditions":"Non Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT01701986","phase":"PHASE1, PHASE2","title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-25","conditions":"Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":64},{"nctId":"NCT03366272","phase":"PHASE2, PHASE3","title":"Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2017-12-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":348},{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416},{"nctId":"NCT06778902","phase":"PHASE2","title":"AZA Combined with R-GemOx for Elderly DLBCL Patients","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-02-01","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":80},{"nctId":"NCT03997968","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cyteir Therapeutics, Inc.","startDate":"2019-10-09","conditions":"Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma","enrollment":169},{"nctId":"NCT06472037","phase":"PHASE2","title":"AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-01","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT02692248","phase":"PHASE2","title":"Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-04-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":64},{"nctId":"NCT06521255","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2024-05-07","conditions":"DLBCL","enrollment":244},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06086197","phase":"PHASE2","title":"A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-10-01","conditions":"Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory","enrollment":41},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT00863369","phase":"PHASE1, PHASE2","title":"Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2005-06-29","conditions":"Lymphoma","enrollment":33},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":"Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma","enrollment":""},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT06062641","phase":"PHASE2","title":"Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-10-30","conditions":"Relapsed or Refractory B-cell Lymphoma","enrollment":50},{"nctId":"NCT04022005","phase":"PHASE2","title":"Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-06-19","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":54},{"nctId":"NCT00078949","phase":"PHASE3","title":"Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-08-27","conditions":"Lymphoma","enrollment":849},{"nctId":"NCT04156828","phase":"PHASE1","title":"Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-03-31","conditions":"Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":12},{"nctId":"NCT05821192","phase":"NA","title":"Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.","status":"UNKNOWN","sponsor":"Ou Bai, MD/PHD","startDate":"2023-03-23","conditions":"Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma","enrollment":34},{"nctId":"NCT03422523","phase":"PHASE2","title":"Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy","status":"TERMINATED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2018-05-09","conditions":"Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":53},{"nctId":"NCT05186558","phase":"PHASE2","title":"Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-05-15","conditions":"Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type","enrollment":54},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT02741388","phase":"PHASE1","title":"A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-10","conditions":"B-cell Lymphoma","enrollment":39},{"nctId":"NCT01321541","phase":"PHASE3","title":"Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2011-04-20","conditions":"Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma","enrollment":312},{"nctId":"NCT04882163","phase":"PHASE1, PHASE2","title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2021-10-10","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT03259529","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL","status":"COMPLETED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2017-03-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT02951156","phase":"PHASE3","title":"Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-12-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT04659434","phase":"PHASE2","title":"Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL","status":"UNKNOWN","sponsor":"Qian Wenbin","startDate":"2020-12-10","conditions":"Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":51},{"nctId":"NCT00436280","phase":"PHASE2","title":"Chemotherapy for Participants With Lymphoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-02","conditions":"Lymphoma, Large Cell, Diffuse","enrollment":68},{"nctId":"NCT04432402","phase":"NA","title":"Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-06-14","conditions":"Diffuse Large B Cell Lymphoma","enrollment":124},{"nctId":"NCT04361409","phase":"PHASE1","title":"Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2013-05","conditions":"Head and Neck Squamous Carcinoma","enrollment":10},{"nctId":"NCT00088530","phase":"PHASE3","title":"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-07","conditions":"Lymphoma, Non-Hodgkin","enrollment":140},{"nctId":"NCT01983969","phase":"PHASE1, PHASE2","title":"Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-11-07","conditions":"Advanced Cancers, Lymphoma","enrollment":61},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT01197560","phase":"PHASE2, PHASE3","title":"Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-09-02","conditions":"Diffuse Large B-cell Lymphoma","enrollment":111},{"nctId":"NCT00003397","phase":"PHASE2","title":"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1998-09","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT02060656","phase":"PHASE2","title":"Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2013-09","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":92},{"nctId":"NCT00875667","phase":"PHASE2","title":"A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-04-30","conditions":"Mantle Cell Lymphoma, Lymphoma, Mantle-Cell","enrollment":254},{"nctId":"NCT04021992","phase":"PHASE2","title":"GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-07-15","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":48},{"nctId":"NCT01055496","phase":"PHASE1","title":"Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Lymphoma, B-Cell","enrollment":103},{"nctId":"NCT02624492","phase":"PHASE2","title":"To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-01-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":21},{"nctId":"NCT01670370","phase":"PHASE2","title":"Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2012-08","conditions":"Diffuse Large B-cell Lymphoma","enrollment":60},{"nctId":"NCT03795571","phase":"PHASE1","title":"Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-01-01","conditions":"Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory","enrollment":12},{"nctId":"NCT01232556","phase":"PHASE3","title":"A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-04-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":338},{"nctId":"NCT02767674","phase":"PHASE3","title":"Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":258},{"nctId":"NCT03719989","phase":"PHASE2","title":"Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-12-01","conditions":"Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":27},{"nctId":"NCT03373019","phase":"PHASE2","title":"Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2017-12-21","conditions":"Chidamide, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse","enrollment":63},{"nctId":"NCT01562977","phase":"PHASE2","title":"Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2011-04","conditions":"Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma","enrollment":82},{"nctId":"NCT00072514","phase":"PHASE2","title":"Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-08","conditions":"Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":55},{"nctId":"NCT02961816","phase":"PHASE2","title":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00881387","phase":"PHASE2","title":"Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2009-02","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00656084","phase":"PHASE2","title":"Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2004-12","conditions":"Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":16},{"nctId":"NCT00410982","phase":"PHASE1","title":"Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":145},{"nctId":"NCT01562990","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-12","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":11},{"nctId":"NCT02701673","phase":"PHASE1, PHASE2","title":"Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00280878","phase":"PHASE2","title":"Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma","status":"COMPLETED","sponsor":"Bayside Health","startDate":"2006-01","conditions":"Non-Hodgkin's Lymphoma (CD20+)","enrollment":12},{"nctId":"NCT01421173","phase":"PHASE1","title":"Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08","conditions":"Lymphoma","enrollment":78},{"nctId":"NCT00169195","phase":"PHASE2","title":"Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-04","conditions":"Diffuse Large Cell Lymphoma","enrollment":49},{"nctId":"NCT00954005","phase":"PHASE1, PHASE2","title":"Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma","status":"TERMINATED","sponsor":"German Low Grade Lymphoma Study Group","startDate":"2003-01","conditions":"Indolent Lymphoma","enrollment":56}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":3,"reaction":"DEATH"},{"count":2,"reaction":"IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME"},{"count":1,"reaction":"APLASTIC ANAEMIA"},{"count":1,"reaction":"B-CELL LYMPHOMA RECURRENT"},{"count":1,"reaction":"BACTERIAL SEPSIS"},{"count":1,"reaction":"CLOSTRIDIUM DIFFICILE INFECTION"},{"count":1,"reaction":"COMPOSITE LYMPHOMA"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"CONSTIPATION"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine + Rituximab","genericName":"Gemcitabine + Rituximab","companyName":"CTI BioPharma","companyId":"cti-biopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine damages cancer cell DNA while rituximab targets and eliminates B cells expressing CD20, combining chemotherapy with immunotherapy. Used for B-cell non-Hodgkin lymphoma, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}